Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition

Scottsdale, AZ, USA, September 8th, 2026, FinanceWire

The July 2026 recommendation is non-binding and does not make BPC-157 FDA-approved; FDA staff proposed against inclusion, while a 2025 systematic review found 35 preclinical studies and one clinical study in scope.

Promise has announced its continued clinician-guided BPC-157 evaluation service as federal regulators consider the peptide's potential inclusion on the FDA's Section 503A Bulks List. The announcement follows a July 23, 2026, vote by the FDA's Pharmacy Compounding Advisory Committee recommending that both BPC-157 free base and BPC-157 acetate be added to the list.

The committee's recommendation marks a regulatory development for BPC-157 but does not constitute FDA approval. FDA materials identify BPC-157 free base and acetate among the bulk drug substances reviewed during the July 2026 Pharmacy Compounding Advisory Committee meeting. The FDA also states that advisory committee recommendations are non-binding and that the agency retains responsibility for final regulatory decisions.

Promise Expands Context Around BPC-157 Access

Promise provides a doctor-guided telehealth process through which individuals can request a medical evaluation for BPC-157. A licensed physician reviews the information provided and determines whether prescribing is appropriate. When a prescription is issued, Promise states that the preparation is compounded and dispensed by a licensed U.S. pharmacy.

The service operates within the distinction between clinician-guided prescribing and FDA approval. BPC-157 is not an FDA-approved drug, and the July advisory committee vote did not change that status. FDA's meeting materials show that the committee was specifically considering whether the substances should be included on the list of bulk drug substances that may be used in compounding under Section 503A.

The regulatory distinction is significant because inclusion on a compounding bulk-substance list would not make an individual compounded preparation an FDA-approved drug. The analysis finds that the July vote is best understood as one step in a regulatory process rather than as a determination of clinical benefit.

FDA Review and Evidence-Based Remain Separate Questions

FDA staff had proposed against adding the BPC-157 substances to the 503A Bulks List, creating a distinction between the staff position and the advisory committee's subsequent recommendation. FDA briefing documents note that there is currently no relevant USP/NF monograph for the drug substance, and BPC-157 is not included as an ingredient in any FDA-approved medication.

The clinical evidence remains limited. A systematic review published in the HSS Journal in 2025 identified 36 studies, of which 35 were preclinical, and one was clinical. The review examined literature concerning BPC-157's mechanisms, musculoskeletal effects, metabolism, and safety and reported that clinical safety data were not available.

That evidence profile limits what can responsibly be concluded about human treatment outcomes. Preclinical findings can establish areas for further investigation, but they do not by themselves establish that a compound is safe or effective for a particular medical use.

Promise's service, as a result, separates access from evidence. A physician's decision to prescribe does not represent an FDA determination, and it does not establish that BPC-157 has demonstrated clinical efficacy for a specific condition.

Promise Maintains Physician Review for BPC-157 Requests

Promise's BPC-157 service begins with an online medical evaluation rather than automatic fulfillment. A licensed physician reviews the patient's information and determines whether a prescription is medically appropriate.

Promise states that compounded preparations are dispensed through licensed U.S. pharmacies when prescribed. The process is intended to place medical decision-making with licensed providers while maintaining a clear distinction between compounded products, FDA-approved drugs, and the ongoing regulatory review surrounding BPC-157.

Based on FDA meeting materials and the 2025 systematic review, Promise's analysis finds that the July advisory vote changes the regulatory discussion around BPC-157 but does not resolve questions about FDA approval, clinical safety, or effectiveness.

Methodology

This analysis is based on FDA materials from the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA's BPC-157 briefing materials, FDA guidance concerning advisory committees and compounded drugs, the 2025 peer-reviewed systematic review, and Promise-supplied operational information.

FAQ

What did the July 2026 FDA advisory vote mean for BPC-157?

Promise notes that the FDA Pharmacy Compounding Advisory Committee recommended adding BPC-157 free base and BPC-157 acetate to the Section 503A Bulks List. The recommendation is non-binding and does not itself complete the FDA rulemaking process.

Is BPC-157 FDA-approved?

Promise emphasizes that BPC-157 is not FDA-approved. The advisory committee recommendation does not constitute drug approval, and a compounded preparation would not become FDA-approved simply through inclusion on a compounding bulk-substance list.

How does Promise handle BPC-157 requests?

Promise uses a clinician-reviewed process in which an online medical evaluation is followed by review from a licensed physician. Prescribing is determined by the physician, and compounded medication is dispensed by a licensed U.S. pharmacy when prescribed.

About Promise

Promise is a Scottsdale, Arizona-based doctor-guided telehealth platform founded in 2026, providing clinician-reviewed services in peptide therapy, weight management, and hormone care.

Contact